A trojan horse selenium-containing polymer for protective co-delivery of Fe(II) and cisplatin to boost chemo-ferroptosis synergy via GSH-triggered ROS storm
Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, is critically influenced by ferrous ions (Fe<sup>2+</sup>) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). However, the inherent instability of Fe<sup>2+</sup> and insufficient levels of endogenous H<sub>2</sub>O<sub>2</sub> within the tumor microenvironment necessitate the combination of current iron-based nanoparticles with other modalities to achieve effective cancer therapy. Herein, we designed a glutathione (GSH)-responsive selenium-containing polymeric nanoreactor co-loaded with Fe<sup>2+</sup> and cisplatin. Selenium-containing polymers can effectively enhance the stability of both Fe<sup>2+</sup> and cisplatin, and undergo cleavage in tumor cells with high GSH levels to achieve specific cisplatin and Fe<sup>2+</sup> release, resulting in a substantial depletion of GSH and downregulation of glutathione peroxidase 4 (GPX-4). More interestingly, cisplatin not only serve as a chemotherapeutic drug, but also promote intracellular H<sub>2</sub>O<sub>2</sub> generation to fuel the Fe<sup>2+</sup>-mediated Fenton reaction, thereby cascading chemotherapy and ferroptosis to effectively kill cancer cells. This GSH-activated selenium-polymer armored Fe<sup>2+</sup>/cisplatin cascade nanoreactor effectively disrupts the anti-ferroptosis system in cancer cells and continuously drives ferroptotic cell death. By overcoming the limitations of current ferroptosis-based cancer therapies, this approach holds great promise for the development of safe, efficient, and precisely controllable ferroptosis-based cancer therapies.
Authors
- Yuting Lin (ORCID: https://orcid.org/0000-0003-1894-8441)
- Zheng Luo (ORCID: https://orcid.org/0000-0002-5093-3058)
- Haili Hu (ORCID: https://orcid.org/0000-0002-0738-8138)
- Xian Jun Loh (ORCID: https://orcid.org/0000-0001-8118-6502)
- Bin Yang (ORCID: https://orcid.org/0000-0001-9416-3094)
- Changliang Ren (ORCID: https://orcid.org/0000-0003-2657-9412)
- Ying Chen (ORCID: https://orcid.org/0000-0001-7754-2367)
- Yun‐Long Wu (ORCID: https://orcid.org/0000-0001-6426-6340)
- Zeyu Zheng (ORCID: https://orcid.org/0000-0002-3083-3324)
- Choon Peng Teng
Institutions
- Agency for Science, Technology and Research (SG)
- Xiamen University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Institute of Materials Research and Engineering (SG)
Publication Details
- Journal
- Materials Today Bio
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1016/j.mtbio.2025.102488
- Citations
- 1
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.67